Lawrence Livermore National Laboratory, Livermore, California.
Synthetic Genomics Vaccine Inc., La Jolla, CA.
Nanomedicine. 2020 Feb;24:102154. doi: 10.1016/j.nano.2020.102154. Epub 2020 Jan 24.
In vivo delivery of large RNA molecules has significant implications for novel gene therapy, biologics delivery, and vaccine applications. We have developed cationic nanolipoprotein particles (NLPs) to enhance the complexation and delivery of large self-amplifying mRNAs (replicons) in vivo. NLPs are high-density lipoprotein (HDL) mimetics, comprised of a discoidal lipid bilayer stabilized by apolipoproteins that are readily functionalized to provide a versatile delivery platform. Herein, we systematically screened NLP assembly with a wide range of lipidic and apolipoprotein constituents, using biophysical metrics to identify lead candidates for in vivo RNA delivery. NLPs formulated with cationic lipids successfully complexed with RNA replicons encoding luciferase, provided measurable protection from RNase degradation, and promoted replicon in vivo expression. The NLP complexation of the replicon and in vivo transfection efficiency were further enhanced by modulating the type and percentage of cationic lipid, the ratio of cationic NLP to replicon, and by incorporating additive molecules.
体内递送大 RNA 分子对新型基因治疗、生物制剂递送和疫苗应用具有重要意义。我们开发了阳离子纳米脂蛋白颗粒(NLPs),以增强大自扩增 mRNA(复制子)在体内的复合物形成和递送。NLPs 是高密度脂蛋白(HDL)模拟物,由载脂蛋白稳定的圆盘状脂质双层组成,易于功能化,提供了一种多功能的递送平台。在此,我们使用生物物理指标系统地筛选了具有广泛脂质和载脂蛋白成分的 NLP 组装,以确定用于体内 RNA 递送的先导候选物。用阳离子脂质制剂的 NLPs 成功地与编码荧光素酶的 RNA 复制子复合物形成,提供了可衡量的对 RNase 降解的保护,并促进了复制子在体内的表达。通过调节阳离子脂质的类型和百分比、阳离子 NLP 与复制子的比例以及添加分子,进一步增强了复制子的 NLP 复合物形成和体内转染效率。